Atopic Dermatitis-Pipeline Review, H2 2016

Atopic Dermatitis-Pipeline Review, H2 2016


  • Products Id :- GMDHC8341IDB
  • |
  • Pages: 375
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Atopic Dermatitis-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Atopic Dermatitis-Pipeline Review, H2 2016', provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis

The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects

The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 11

Introduction 12

Global Markets Direct Report Coverage 12

Atopic Dermatitis Overview 13

Therapeutics Development 14

Pipeline Products for Atopic Dermatitis-Overview 14

Pipeline Products for Atopic Dermatitis-Comparative Analysis 15

Atopic Dermatitis-Therapeutics under Development by Companies 16

Atopic Dermatitis-Therapeutics under Investigation by Universities/Institutes 22

Atopic Dermatitis-Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Unknown Stage Products 26

Atopic Dermatitis-Products under Development by Companies 27

Atopic Dermatitis-Products under Investigation by Universities/Institutes 35

Atopic Dermatitis-Companies Involved in Therapeutics Development 36

AbbVie Inc 36

Accolade Pharmaceuticals, LLC 37

AlbireoPharma 38

Almirall, S.A. 39

Amgen Inc. 40

Amorepacific Corporation 41

Anacor Pharmaceuticals, Inc. 42

AnaMar AB 43

AnaptysBio, Inc. 44

AnGes MG, Inc. 45

arGEN-X BV 46

Avexxin AS 47

Blueberry Therapeutics Ltd 48

Brickell Biotech, Inc. 49

Celgene Corporation 50

Cell Medica Limited 51

Cellceutix Corporation 52

ChemoCentryx, Inc. 53

ChironWells GmbH 54

Chugai Pharmaceutical Co., Ltd. 55

Creabilis SA 56

Curapel Limited 57

Dermala Inc 58

Dr. August Wolff GmbH & Co. KG Arzneimittle 59

Eli Lilly and Company 60

F. Hoffmann-La Roche Ltd. 61

Foamix Pharmaceuticals Ltd. 62

Fountain Biopharma Inc. 63

Galapagos NV 64

GlaxoSmithKline Plc 65

Glenmark Pharmaceuticals Ltd. 66

Grupo Ferrer Internacional, S.A. 67

Han Wha Pharma Co., Ltd. 68

HanAll Biopharma Co., Ltd. 69

Heptares Therapeutics Limited 70

Herantis Pharma Plc 71

iCo Therapeutics Inc. 72

Immune Pharmaceuticals Inc. 73

Inflamalps SA 74

Japan Tobacco Inc. 75

Johnson & Johnson 76

Kang Stem Biotech Co., Ltd. 77

KPI Therapeutics, Inc. 78

LegoChem Biosciences, Inc 79

LEO Pharma A/S 80

Madam Therapeutics B.V. 81

MedImmune, LLC 82

NeoPharm Co., Ltd. 83

Nippon Shinyaku Co., Ltd. 84

Novan, Inc. 85

Novartis AG 86

Orbis Biosciences Inc 87

Otsuka Holdings Co., Ltd. 88

Oxagen Limited 89

Pfizer Inc. 90

Pharis Biotec GmbH 91

Pharmedartis GmbH 92

Provectus Biopharmaceuticals, Inc. 93

PuriCore Plc 94

Quorum Innovations LLC 95

Regeneron Pharmaceuticals Inc 96

Signum Dermalogix, Inc 97

Spherium Biomed S.L. 98

sterna biologicals Gmbh & Co KG 99

Sucampo Pharmaceuticals, Inc. 100

Sun Pharma Advanced Research Company Ltd. 101

SWITCH Biotech LLC 102

Takeda Pharmaceutical Company Limited 103

Thesan Pharmaceuticals, Inc. 104

Tioga Pharmaceuticals, Inc. 105

Torrent Pharmaceuticals Limited 106

Valeant Pharmaceuticals International, Inc. 107

Vicore Pharma AB 108

Vitae Pharmaceuticals, Inc. 109

VivaCell Biotechnology Espana S.L. 110

Xencor, Inc. 111

Ziarco Pharma Ltd 112

Atopic Dermatitis-Therapeutics Assessment 113

Assessment by Monotherapy Products 113

Assessment by Target 114

Assessment by Mechanism of Action 119

Assessment by Route of Administration 124

Assessment by Molecule Type 126

Drug Profiles 128

A-3914-Drug Profile 128

A-5425-Drug Profile 129

AKP-11-Drug Profile 130

Allergen for House Dust Mite Induced Atopic Dermatitis-Drug Profile 132

ALX-101-Drug Profile 133

AM-1030-Drug Profile 134

AMG-0101-Drug Profile 135

Anatabine-Drug Profile 137

ANB-020-Drug Profile 140

apremilast-Drug Profile 142

Aptamers to Inhibit Galectin-3 for Atopic Dermatitis-Drug Profile 153

ARGX-112-Drug Profile 154

ARN-077-Drug Profile 155

asimadoline-Drug Profile 156

AVX-001-Drug Profile 158

B-244-Drug Profile 159

baricitinib-Drug Profile 160

BB-2702-Drug Profile 167

BBI-2000-Drug Profile 168

BBI-5000-Drug Profile 169

bertilimumab-Drug Profile 170

betamethasone valerate-Drug Profile 174

Biologic for Atopic Dermatitis and Eczema-Drug Profile 175

brilacidin tetrahydrochloride-Drug Profile 176

BTX-1204-Drug Profile 185

C-21-Drug Profile 186

CBP-174-Drug Profile 188

CBP-201-Drug Profile 189

CCX-6239-Drug Profile 190

CDE-001-Drug Profile 191

Cis-Urocanic Acid-Drug Profile 192

cobamamide-Drug Profile 195

crisaborole-Drug Profile 196

CT-101-Drug Profile 201

CT-103-Drug Profile 202

CT-327-Drug Profile 203

CT-340-Drug Profile 206

cyclosporine-Drug Profile 207

dalazatide-Drug Profile 208

DMT-210-Drug Profile 213

Drug for Atopic Dermatitis-Drug Profile 214

dupilumab-Drug Profile 215

FB-825-Drug Profile 221

fevipiprant-Drug Profile 222

FIB-116-Drug Profile 224

Furestem-AD-Drug Profile 225

GBR-830-Drug Profile 226

GLPG-2534-Drug Profile 227

GSK-3772847A-Drug Profile 228

Histimex-Drug Profile 229

HS-378-Drug Profile 230

IDP-124-Drug Profile 231

JTE-052-Drug Profile 232

KPI-150-Drug Profile 233

LCB-030110-Drug Profile 234

lebrikizumab-Drug Profile 235

LEKTI-6-Drug Profile 238

LEO-32731-Drug Profile 239

LEO-39652-Drug Profile 240

MEDI-9314-Drug Profile 241

mepolizumab-Drug Profile 242

MLR-1130-Drug Profile 247

mometasone furoate-Drug Profile 248

Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation-Drug Profile 249

Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis-Drug Profile 250

Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer-Drug Profile 251

N-oleoylethanolamine-Drug Profile 252

nemolizumab-Drug Profile 253

NPH-12-Drug Profile 254

NS-141-Drug Profile 255

OC-000459-Drug Profile 256

OC-2417-Drug Profile 258

octenidine hydrochloride-Drug Profile 259

OLX-103-Drug Profile 260

omiganan pentahydrochloride-Drug Profile 261

OPA-15406-Drug Profile 263

P-10-Drug Profile 265

P-148-Drug Profile 266

PAC-14028-Drug Profile 267

Peptide to Antagonize CX3CR1 for Atopic Dermatitis-Drug Profile 269

Peptides to Antagonize TNFR-1 for Atopic Dermatitis-Drug Profile 270

PF-04965842-Drug Profile 271

PH-10-Drug Profile 272

PL-601-Drug Profile 275

PMA-101R-Drug Profile 276

PMA-201-Drug Profile 277

PMA-411R-Drug Profile 278

PR-022-Drug Profile 279

prednisone-Drug Profile 280

PZ-235-Drug Profile 281

Q-301-Drug Profile 282

Qi-507-Drug Profile 283

roflumilast-Drug Profile 284

RTU-1096-Drug Profile 289

RVT-501-Drug Profile 291

SB-011-Drug Profile 292

SB-414-Drug Profile 293

secukinumab-Drug Profile 294

SIG-1311-Drug Profile 307

SIG-1322-Drug Profile 308

Small Molecule for Atopic Dermatitis-Drug Profile 309

Small Molecule to Modulate S1PR1 for Atopic Dermatitis-Drug Profile 310

Small Molecules for Atopic Dermatitis-Drug Profile 311

Small Molecules for Atopic Dermatitis-Drug Profile 312

Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis-Drug Profile 313

SP-14019-Drug Profile 314

SUN-0597-Drug Profile 315

SWT-01113-Drug Profile 317

SWT-05141-Drug Profile 318

Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders-Drug Profile 319

tacrolimus-Drug Profile 320

tezepelumab-Drug Profile 321

tralokinumab-Drug Profile 323

upadacitinib tartrate-Drug Profile 325

ustekinumab-Drug Profile 327

VTP-38543-Drug Profile 333

WBI-1001-Drug Profile 334

WOL-071007-Drug Profile 336

XmAb-7195-Drug Profile 337

YJC-10592-Drug Profile 338

Zafi-1-Drug Profile 339

ZPL-389-Drug Profile 340

ZPL-521-Drug Profile 342

Atopic Dermatitis-Dormant Projects 343

Atopic Dermatitis-Discontinued Products 353

Atopic Dermatitis-Product Development Milestones 355

Featured News & Press Releases 355

Appendix 365

Methodology 365

Coverage 365

Secondary Research 365

Primary Research 365

Expert Panel Validation 365

Contact Us 365

Disclaimer 366

List of Tables

Number of Products under Development for Atopic Dermatitis, H2 2016 23

Number of Products under Development for Atopic Dermatitis-Comparative Analysis, H2 2016 24

Number of Products under Development by Companies, H2 2016 25

Number of Products under Development by Companies, H2 2016 (Contd..1) 26

Number of Products under Development by Companies, H2 2016 (Contd..2) 27

Number of Products under Development by Companies, H2 2016 (Contd..3) 28

Number of Products under Development by Companies, H2 2016 (Contd..4) 29

Number of Products under Development by Companies, H2 2016 (Contd..5) 30

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Late Stage Development, H2 2016 32

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Development, H2 2016 34

Comparative Analysis by Unknown Stage Development, H2 2016 35

Products under Development by Companies, H2 2016 36

Products under Development by Companies, H2 2016 (Contd..1) 37

Products under Development by Companies, H2 2016 (Contd..2) 38

Products under Development by Companies, H2 2016 (Contd..3) 39

Products under Development by Companies, H2 2016 (Contd..4) 40

Products under Development by Companies, H2 2016 (Contd..5) 41

Products under Development by Companies, H2 2016 (Contd..6) 42

Products under Development by Companies, H2 2016 (Contd..7) 43

Products under Investigation by Universities/Institutes, H2 2016 44

Atopic Dermatitis-Pipeline by AbbVie Inc, H2 2016 45

Atopic Dermatitis-Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 46

Atopic Dermatitis-Pipeline by AlbireoPharma, H2 2016 47

Atopic Dermatitis-Pipeline by Almirall, S.A., H2 2016 48

Atopic Dermatitis-Pipeline by Amgen Inc., H2 2016 49

Atopic Dermatitis-Pipeline by Amorepacific Corporation, H2 2016 50

Atopic Dermatitis-Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 51

Atopic Dermatitis-Pipeline by AnaMar AB, H2 2016 52

Atopic Dermatitis-Pipeline by AnaptysBio, Inc., H2 2016 53

Atopic Dermatitis-Pipeline by AnGes MG, Inc., H2 2016 54

Atopic Dermatitis-Pipeline by arGEN-X BV, H2 2016 55

Atopic Dermatitis-Pipeline by Avexxin AS, H2 2016 56

Atopic Dermatitis-Pipeline by Blueberry Therapeutics Ltd, H2 2016 57

Atopic Dermatitis-Pipeline by Brickell Biotech, Inc., H2 2016 58

Atopic Dermatitis-Pipeline by Celgene Corporation, H2 2016 59

Atopic Dermatitis-Pipeline by Cell Medica Limited, H2 2016 60

Atopic Dermatitis-Pipeline by Cellceutix Corporation, H2 2016 61

Atopic Dermatitis-Pipeline by ChemoCentryx, Inc., H2 2016 62

Atopic Dermatitis-Pipeline by ChironWells GmbH, H2 2016 63

Atopic Dermatitis-Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 64

Atopic Dermatitis-Pipeline by Creabilis SA, H2 2016 65

Atopic Dermatitis-Pipeline by Curapel Limited, H2 2016 66

Atopic Dermatitis-Pipeline by Dermala Inc, H2 2016 67

Atopic Dermatitis-Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016 68

Atopic Dermatitis-Pipeline by Eli Lilly and Company, H2 2016 69

Atopic Dermatitis-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 70

Atopic Dermatitis-Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 71

Atopic Dermatitis-Pipeline by Fountain Biopharma Inc., H2 2016 72

Atopic Dermatitis-Pipeline by Galapagos NV, H2 2016 73

Atopic Dermatitis-Pipeline by GlaxoSmithKline Plc, H2 2016 74

Atopic Dermatitis-Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 75

Atopic Dermatitis-Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 76

Atopic Dermatitis-Pipeline by Han Wha Pharma Co., Ltd., H2 2016 77

Atopic Dermatitis-Pipeline by HanAll Biopharma Co., Ltd., H2 2016 78

Atopic Dermatitis-Pipeline by Heptares Therapeutics Limited, H2 2016 79

Atopic Dermatitis-Pipeline by Herantis Pharma Plc, H2 2016 80

Atopic Dermatitis-Pipeline by iCo Therapeutics Inc., H2 2016 81

Atopic Dermatitis-Pipeline by Immune Pharmaceuticals Inc., H2 2016 82

Atopic Dermatitis-Pipeline by Inflamalps SA, H2 2016 83

Atopic Dermatitis-Pipeline by Japan Tobacco Inc., H2 2016 84

Atopic Dermatitis-Pipeline by Johnson & Johnson, H2 2016 85

Atopic Dermatitis-Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 86

Atopic Dermatitis-Pipeline by KPI Therapeutics, Inc., H2 2016 87

Atopic Dermatitis-Pipeline by LegoChem Biosciences, Inc, H2 2016 88

Atopic Dermatitis-Pipeline by LEO Pharma A/S, H2 2016 89

Atopic Dermatitis-Pipeline by Madam Therapeutics B.V., H2 2016 90

Atopic Dermatitis-Pipeline by MedImmune, LLC, H2 2016 91

Atopic Dermatitis-Pipeline by NeoPharm Co., Ltd., H2 2016 92

Atopic Dermatitis-Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 93

Atopic Dermatitis-Pipeline by Novan, Inc., H2 2016 94

Atopic Dermatitis-Pipeline by Novartis AG, H2 2016 95

Atopic Dermatitis-Pipeline by Orbis Biosciences Inc, H2 2016 96

Atopic Dermatitis-Pipeline by Otsuka Holdings Co., Ltd., H2 2016 97

Atopic Dermatitis-Pipeline by Oxagen Limited, H2 2016 98

Atopic Dermatitis-Pipeline by Pfizer Inc., H2 2016 99

Atopic Dermatitis-Pipeline by Pharis Biotec GmbH, H2 2016 100

Atopic Dermatitis-Pipeline by Pharmedartis GmbH, H2 2016 101

Atopic Dermatitis-Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 102

Atopic Dermatitis-Pipeline by PuriCore Plc, H2 2016 103

Atopic Dermatitis-Pipeline by Quorum Innovations LLC, H2 2016 104

Atopic Dermatitis-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 105

Atopic Dermatitis-Pipeline by Signum Dermalogix, Inc, H2 2016 106

Atopic Dermatitis-Pipeline by Spherium Biomed S.L., H2 2016 107

Atopic Dermatitis-Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 108

Atopic Dermatitis-Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 109

Atopic Dermatitis-Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 110

Atopic Dermatitis-Pipeline by SWITCH Biotech LLC, H2 2016 111

Atopic Dermatitis-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 112

Atopic Dermatitis-Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 113

Atopic Dermatitis-Pipeline by Tioga Pharmaceuticals, Inc., H2 2016 114

Atopic Dermatitis-Pipeline by Torrent Pharmaceuticals Limited, H2 2016 115

Atopic Dermatitis-Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 116

Atopic Dermatitis-Pipeline by Vicore Pharma AB, H2 2016 117

Atopic Dermatitis-Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 118

Atopic Dermatitis-Pipeline by VivaCell Biotechnology Espana S.L., H2 2016 119

Atopic Dermatitis-Pipeline by Xencor, Inc., H2 2016 120

Atopic Dermatitis-Pipeline by Ziarco Pharma Ltd, H2 2016 121

Assessment by Monotherapy Products, H2 2016 122

Number of Products by Stage and Target, H2 2016 124

Number of Products by Stage and Mechanism of Action, H2 2016 129

Number of Products by Stage and Route of Administration, H2 2016 134

Number of Products by Stage and Molecule Type, H2 2016 136

Atopic Dermatitis-Dormant Projects, H2 2016 352

Atopic Dermatitis-Dormant Projects (Contd..1), H2 2016 353

Atopic Dermatitis-Dormant Projects (Contd..2), H2 2016 354

Atopic Dermatitis-Dormant Projects (Contd..3), H2 2016 355

Atopic Dermatitis-Dormant Projects (Contd..4), H2 2016 356

Atopic Dermatitis-Dormant Projects (Contd..5), H2 2016 357

Atopic Dermatitis-Dormant Projects (Contd..6), H2 2016 358

Atopic Dermatitis-Dormant Projects (Contd..7), H2 2016 359

Atopic Dermatitis-Dormant Projects (Contd..8), H2 2016 360

Atopic Dermatitis-Dormant Projects (Contd..9), H2 2016 361

Atopic Dermatitis-Discontinued Products, H2 2016 362

Atopic Dermatitis-Discontinued Products (Contd..1), H2 2016 363

List of Figures

Number of Products under Development for Atopic Dermatitis, H2 2016 23

Number of Products under Development for Atopic Dermatitis-Comparative Analysis, H2 2016 24

Number of Products under Development by Companies, H2 2016 25

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Late Stage Development, H2 2016 32

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Products, H2 2016 34

Assessment by Monotherapy Products, H2 2016 122

Number of Products by Top 10 Targets, H2 2016 123

Number of Products by Stage and Top 10 Targets, H2 2016 123

Number of Products by Top 10 Mechanism of Actions, H2 2016 128

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 128

Number of Products by Top 10 Routes of Administration, H2 2016 133

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 133

Number of Products by Top 10 Molecule Types, H2 2016 135

Number of Products by Stage and Top 10 Molecule Types, H2 2016 135

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

Accolade Pharmaceuticals, LLC

AlbireoPharma

Almirall, S.A.

Amgen Inc.

Amorepacific Corporation

Anacor Pharmaceuticals, Inc.

AnaMar AB

AnaptysBio, Inc.

AnGes MG, Inc.

arGEN-X BV

Avexxin AS

Blueberry Therapeutics Ltd

Brickell Biotech, Inc.

Celgene Corporation

Cell Medica Limited

Cellceutix Corporation

ChemoCentryx, Inc.

ChironWells GmbH

Chugai Pharmaceutical Co., Ltd.

Creabilis SA

Curapel Limited

Dermala Inc

Dr. August Wolff GmbH & Co. KG Arzneimittle

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Foamix Pharmaceuticals Ltd.

Fountain Biopharma Inc.

Galapagos NV

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

Grupo Ferrer Internacional, S.A.

Han Wha Pharma Co., Ltd.

HanAll Biopharma Co., Ltd.

Heptares Therapeutics Limited

Herantis Pharma Plc

iCo Therapeutics Inc.

Immune Pharmaceuticals Inc.

Inflamalps SA

Japan Tobacco Inc.

Johnson & Johnson

Kang Stem Biotech Co., Ltd.

KPI Therapeutics, Inc.

LegoChem Biosciences, Inc

LEO Pharma A/S

Madam Therapeutics B.V.

MedImmune, LLC

NeoPharm Co., Ltd.

Nippon Shinyaku Co., Ltd.

Novan, Inc.

Novartis AG

Orbis Biosciences Inc

Otsuka Holdings Co., Ltd.

Oxagen Limited

Pfizer Inc.

Pharis Biotec GmbH

Pharmedartis GmbH

Provectus Biopharmaceuticals, Inc.

PuriCore Plc

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Signum Dermalogix, Inc

Spherium Biomed S.L.

sterna biologicals Gmbh & Co KG

Sucampo Pharmaceuticals, Inc.

Sun Pharma Advanced Research Company Ltd.

SWITCH Biotech LLC

Takeda Pharmaceutical Company Limited

Thesan Pharmaceuticals, Inc.

Tioga Pharmaceuticals, Inc.

Torrent Pharmaceuticals Limited

Valeant Pharmaceuticals International, Inc.

Vicore Pharma AB

Vitae Pharmaceuticals, Inc.

VivaCell Biotechnology Espana S.L.

Xencor, Inc.

Ziarco Pharma Ltd

Atopic Dermatitis Therapeutic Products under Development, Key Players in Atopic Dermatitis Therapeutics, Atopic Dermatitis Pipeline Overview, Atopic Dermatitis Pipeline, Atopic Dermatitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 142760
Site License
USD 4000 INR 285520
Corporate User License
USD 6000 INR 428280

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com